Group 1 - The core viewpoint of the article highlights that Beida Pharmaceutical (300558) is experiencing steady sales growth for its eight listed drugs and is gradually expanding into overseas markets [1] - The company is concentrating resources on the development of key projects and is increasing its investment in new targets and technologies to expedite the launch of new products [1]

Core Viewpoint - The company reported a revenue of 2.717 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 15.90% [2] - The EBITDA reached 860 million yuan, showing a year-on-year increase of 20.15%, although net profit did not grow at the same rate due to depreciation and amortization factors [2] Group 1 - The company currently has eight listed drugs, and revenue is expected to improve as drug promotion strategies are implemented [2] - The company is actively monitoring advancements in new drug development and plans to align its growth strategy accordingly [2]